非那沙星
| CAS号 | 209342-40-5 | 货号 | BCP23882 |
| 中文名 | 非那沙星 | ||
| 英文名 | Finafloxacin | ||
| 中文别名 | |||
| 英文别名 | BAY35-3377; | ||
| 分子式 | C20H19FN4O4 | 分子量 | 398.39 |
| 生物活性 | Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments. It is being developed by MerLion Pharmaceuticals to treat serious bacterial infections associated with an acidic environment, including urinary tract infections and Helicobacter pylori infections. An otic suspension of finafloxacin (Xtoro™), developed by Alcon (a division of Novartis), was approved in 2014 in the USA for the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Oral and/or intravenous formulations are in phase I and II evaluation in uncomplicated urinary tract infections (Germany and Singapore), complicated urinary tract infections and pyelonephritis (Germany and Poland) and H. pylori infection (Germany). | ||
| 信号通路 | Others Pathway | ||
| 靶 点 | Others | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！